Melanoma News and Research

Latest Melanoma News and Research

Health Canada approves Zyclara Cream for multiple actinic keratoses

Health Canada has approved Zyclara™ (imiquimod) Cream 3.75%, a topical prescription treatment for multiple actinic keratoses (AK) located on the face or balding scalp in adults. Actinic Keratosis is a common skin condition that can lead to squamous cell carcinoma, a form of non-melanoma skin cancer, if left untreated.

6 Jan 2010

Anti-inflammatory prescription drug reduces the risk of common skin cancer in humans

A widely-available anti-inflammatory prescription drug can reduce the risk of a common skin cancer in humans, according to a researcher at Stanford's School of Medicine.

5 Jan 2010

Phase 3 trial of figitumumab discontinued by Pfizer

Pfizer Inc. announced today the discontinuation of A4021016 (also known as ADVIGO 1016), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC) due to the study meeting predefined boundaries for early termination.

30 Dec 2009

Self-seeding process of cancer cells can enhance tumor growth, says study

Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs.

27 Dec 2009

E2F1 transcription factor inhibition reduces EGFR expression and invasive potential of melanoma cells

Inhibition of transcription factor E2F1 reduced epidermal growth factor receptor (EGFR) expression and reduced the invasive potential but not proliferation of metastatic melanoma cells, according to a brief communication published online December 23 in the Journal of the National Cancer Institute.

24 Dec 2009

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a novel chemical structure.

23 Dec 2009

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

No two tumors are alike, but analyzing the genetics of cancers from different parts of the body may reveal surprising details useful for treatment and prevention.

22 Dec 2009

AADA lauds indoor tanning tax in the health system reform legislation

The American Academy of Dermatology Association (AADA) applauds the decision of the U.S. Senate to substitute a 10 percent federal excise tax on indoor tanning services for the proposed tax on cosmetic procedures in the Senate's health system reform legislation (H.R. 3590, the Patient Protection and Affordability Act of 2009). The indoor tanning tax, as proposed to Senate leadership by the AADA, furthers its goal of promoting wellness and prevention, and removes the harmful unintended consequences associated with a tax on cosmetic surgery procedures.

22 Dec 2009

Persistent disparities exist in melanoma diagnosis

White and Hispanic individuals are being diagnosed with melanoma more frequently in recent years, whereas Hispanic and black patients continue to have advanced skin cancer at diagnosis, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals.

22 Dec 2009

Heart transplant patients face increased risk for skin cancers

Many heart transplant patients develop multiple skin cancers, with increased risk for some skin cancers among patients with other cancers and with increasing age, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals.

22 Dec 2009

ZymoGenetics restructures license and collaboration agreements on RECOTHROM

ZymoGenetics, Inc. today announced a restructuring of the U.S. co-promotion and ex-U.S. license and collaboration agreements with Bayer Schering Pharma AG and Bayer HealthCare relating to RECOTHROM® Thrombin, topical (Recombinant).

21 Dec 2009

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.

21 Dec 2009

Phase 2 clinical study of STA-9090 in NSCLC initiated

18 Dec 2009

Typical smoker acquires one mutation for every 15 cigarettes and all cancers are caused by mutations

Research teams led by the Wellcome Trust Sanger Institute announce the first comprehensive analyses of cancer genomes.

17 Dec 2009

AAD's National Melanoma/Skin Cancer Screening Program reaches milestone

One person dies from melanoma, the deadliest form of skin cancer, almost every hour. Yet melanoma is often successfully treated, if caught early. That's why thousands of dermatologists across the country offer free skin cancer screenings in their communities through the American Academy of Dermatology's (AAD) National Melanoma/Skin Cancer Screening Program.

17 Dec 2009

JCTM established to advance new research toward clinical applications

The California Institute of Technology (Caltech) and the University of California, Los Angeles (UCLA) have announced the establishment of the Joint Center for Translational Medicine (JCTM), which will advance experimental research into clinical applications, including the diagnosis and therapy of diseases such as cancer.

17 Dec 2009

GlobalHealth Education & Training service established to meet growing demand in healthcare

Long-time healthcare education business owner, Deborah Kann Schwarzberg, has established GlobalHealth Education & Training®, a corporate training and degree-granting educational service. GlobalHealth was formed to respond to the growing demand for trained employees and management within the healthcare and ancillary industries to enhance their formal education and attain advanced degrees online.

16 Dec 2009

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces the approval from the French Drug Agency (AFFSSaPS) to enter Phase II clinical trial for clonidine Lauriad® in radiotherapy and chemotherapy-induced oral mucositis and the approval from Danish and Slovene Agencies to enter Phase I clinical trial for AMEPTM in invasive melanoma.

15 Dec 2009

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Researchers at the Los Angeles Biomedical Research Institute (LA BioMed) expect to receive more than $4.5 million in grants from the American Recovery and Reinvestment Act (Recovery Act.), including nearly $1 million from the highly competitive Challenge Grant program for a study that seeks to reduce the number of children who die from Sudden Infant Death Syndrome, it was announced today.

15 Dec 2009

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

A novel class of cancer therapies called live biologics is offering new hope for patients affected by hard-to-treat cancers, according to two different studies testing the therapies in patients with sarcomas and head and neck cancers.

14 Dec 2009

Melanoma News and Research

Latest Melanoma News and Research

Health Canada approves Zyclara Cream for multiple actinic keratoses

Anti-inflammatory prescription drug reduces the risk of common skin cancer in humans

Phase 3 trial of figitumumab discontinued by Pfizer

Self-seeding process of cancer cells can enhance tumor growth, says study

E2F1 transcription factor inhibition reduces EGFR expression and invasive potential of melanoma cells

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

AADA lauds indoor tanning tax in the health system reform legislation

Persistent disparities exist in melanoma diagnosis

Heart transplant patients face increased risk for skin cancers

ZymoGenetics restructures license and collaboration agreements on RECOTHROM

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Phase 2 clinical study of STA-9090 in NSCLC initiated

Typical smoker acquires one mutation for every 15 cigarettes and all cancers are caused by mutations

AAD's National Melanoma/Skin Cancer Screening Program reaches milestone

JCTM established to advance new research toward clinical applications

GlobalHealth Education & Training service established to meet growing demand in healthcare

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Melanoma News and Research

Latest Melanoma News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in